Key result
Paclitaxel-coated DCBs yield an ~8% 1-year major cardiovascular events rate in complex coronary lesions.
Why the study?
Drug-coated balloons offer a metal-free revascularization option for selected coronary lesions, but real-world data on procedural and 1-year outcomes in complex coronary lesions remain limited.
Cohort (n=76)
No
Paclitaxel-coated balloon angioplasty (both DCB-only and hybrid strategies) demonstrates high procedural success (87.2%) and low 1-year MACE (7.8%) in real-world complex coronary lesions.
Answers are grounded in this paper and cite their sources.
May support DCB consideration in complex lesions; extends real-world data but leaves open randomized confirmation.
Background Drug-coated balloons (DCBs) offer a metal-free revascularization option for selected coronary lesions, but real-world data remain limited. We evaluated procedural and 1-year outcomes of DCB angioplasty. Methods This retrospective single-center study included patients undergoing PCI with paclitaxel-coated DCBs (2023–2025). Clinical, angiographic, and procedural data were analyzed. Lesions were prepared with 1:1 semi/non-compliant balloons. The primary endpoint was 1-year MACE (all-cause mortality, MI, TVR, or stroke). Results 76 patients (mean age 62 years; 73.7% male) were treated; 67.1% diabetics and 73.7% hypertensive. Lesions were de novo (85.5%), ISR (10.5%), SVG-ISR (2.6%), or de novo SVG (1.3%); 40.8% bifurcation, 28.9% calcified, and 47.3% involved large vessels. DCB-only PCI was performed in 89.5% and hybrid DCB-stent PCI in 10.5%. Mean minimal lumen diameter increased from 0.73 to 1.96 mm (acute gain 1.17 mm). Procedural success (residual stenosis <30% without flow-limiting dissection) was 87.2%; bailout stenting in 7.0% and dissections >Type B in 5.0%. At 1 year, TVR, MACE, and CVS mortality were 1.3, 7.8, and 1.3%, respectively. No MACE or TVR occurred in the hybrid group vs. 8.8 and 2.9% with DCB-only PCI. Increasing age, diabetes, and hypertension independently predicted MACE, whereas ISR treatment and greater acute luminal gain predicted lower risk. Conclusions DCB angioplasty achieved favorable procedural success and low 1-year adverse events in complex coronary lesions. Both DCB-only and hybrid strategies were feasible, supporting DCB-based revascularization in selected patients.
No takes yet. Share an insight, caveat, or question.
Zehra et al. (2026) conducted a cohort in Complex coronary lesions (n=76). Paclitaxel-coated drug-coated balloon (DCB) angioplasty was evaluated on 1-year MACE (all-cause mortality, MI, TVR, or stroke). Paclitaxel-coated DCB angioplasty achieved 87.2% procedural success and a 7.8% 1-year major cardiovascular events rate in patients with complex coronary lesions.
Synapse has enriched 10 related papers. Consider them for comparative context: